Photoplethysmography (PPG) Algorithm with Smartwatch in Evaluation of Atrial Fibrillation Burden After Catheter Ablation (Polaris-AFCA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Song ZUO, M.D
- Phone Number: 1880142775
- Email: song_zuo@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Beijing Anzhen Hospital
-
Contact:
- Song ZUO, M.D
- Phone Number: 1880142775
- Email: song_zuo@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Atrial fibrillation patients diagnosed by electrocardiogram
- Received catheter ablation procedure
- Willing to use long-range electrocardiogram monitoring equipment
Exclusion Criteria:
1.Patients who are allergic to electronic devices or unable to wear watches
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Stroke
Time Frame: March 30, 2025 to March 30, 2035
|
The rate of stroke occurrences in the study population, measured separately for each participant.
The unit of measure will be the frequency of events (e.g., number of strokes per participant).
|
March 30, 2025 to March 30, 2035
|
|
Incidence of Heart Failure
Time Frame: March 30, 2025 to March 30, 2035
|
The rate of heart failure occurrences in the study population, measured separately for each participant.
The unit of measure will be the frequency of events (e.g., number of heart failure episodes per participant).
|
March 30, 2025 to March 30, 2035
|
|
All-Cause Mortality Rate
Time Frame: March 30, 2025 to March 30, 2035
|
The rate of all-cause mortality in the study population, measured separately for each participant.
The unit of measure will be the frequency of events (e.g., number of deaths per participant).
|
March 30, 2025 to March 30, 2035
|
|
Cardiovascular Mortality Rate
Time Frame: March 30, 2025 to March 30, 2035
|
The rate of cardiovascular-related mortality in the study population, measured separately for each participant.
The unit of measure will be the frequency of events (e.g., number of cardiovascular-related deaths per participant).
|
March 30, 2025 to March 30, 2035
|
|
Rate of Rehospitalization
Time Frame: March 30, 2025 to March 30, 2035
|
The rate of rehospitalization due to any medical cause in the study population.
The unit of measure will be the frequency of events (e.g., number of rehospitalization events per participant).
|
March 30, 2025 to March 30, 2035
|
|
Incidence of Bleeding Events
Time Frame: March 30, 2025 to March 30, 2035
|
The rate of bleeding events (such as major or minor bleeding) in the study population.
The unit of measure will be the frequency of events (e.g., number of bleeding events per participant).
|
March 30, 2025 to March 30, 2035
|
|
Postoperative Atrial Fibrillation Burden
Time Frame: March 30, 2025 to March 30, 2035
|
The frequency and severity of atrial fibrillation episodes observed in participants after a surgical procedure, measured using data collected by an intelligent heart rate monitoring watch utilizing a PPG algorithm.
The unit of measure will be frequency of events (e.g., number of episodes per participant).
|
March 30, 2025 to March 30, 2035
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KS2024101 (Other Identifier: Chengdu Xinjikang Technology Co., Ltd)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.